hVIVO plc
("hVIVO", the "Company" or the "Group")
hVIVO to present at Jefferies London Healthcare Conference
hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that Yamin 'Mo' Khan, Chief Executive Officer, will be presenting in-person at the Jefferies Healthcare Conference in
The Jefferies Conference is the largest healthcare-dedicated conference in
For further information please contact:
hVIVO plc |
+44 (0) 20 7756 1300 |
|||
Yamin 'Mo' Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer |
|
|||
|
|
|||
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker) |
+44 (0) 20 7220 0500 |
|||
Geoff Nash, Camilla Hume, Harriet Ward Nigel Birks - Life Science Specialist Sales Louise Talbot - Sales |
|
|||
|
|
|||
Peel Hunt LLP (Joint Broker) |
+44 (0)20 7418 8900 |
|||
James Steel, Dr Christopher Golden |
|
|||
|
|
|||
Davy (Euronext Growth Adviser and Joint Broker) |
+353 (0) 1 679 6363 |
|||
Anthony Farrell, Niall Gilchrist |
|
|||
|
|
|||
Walbrook PR (Financial PR & IR) Paul McManus / Phillip Marriage / |
+44 (0) 20 7933 8780 or hvivo@walbrookpr.com +44 (0) 7980 541 893 / +44 (0) 7867 984 082 / |
|||
Notes to Editors
hVIVO plc (ticker: HVO) is a fast-growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.
The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Group has world class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group also offers additional clinical field trial services such as patient recruitment and clinical trial site services.
hVIVO runs challenge trials in
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.